On the other hand, it was shown that c-MET aberrant activation can promote glioma cell survival via PI3-kinase/Akt signaling [75], squamous cell carcinoma invasion via STAT3 signaling [76], lymphoma cell adhesion via PI3K signaling [77], head and neck squamous cell carcinoma (HNSCC) proliferation via MAPK signaling [78], gastric cancer growth via Akt and Erk signaling [79], prostate cancer EMT and invasion via Erk/MAPK signaling [80], and breast carcinoma cell motility and lung cancer invasion via FAK signaling [81,82]. The gene discussed is MET; the disease is breast carcinoma.